A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical trial NCT05075564 · COMPLETED

Trial details

NCT number: NCT05075564
Sponsor: Elpiscience Biopharma, Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2021-12-23
Primary completion: 2022-10-13
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.